Spotlight on necitumumab in the treatment of non-small-cell lung carcinoma

Manish K Thakur, Antoinette J Wozniak, Department of Oncology, Karmanos Cancer Center, Detroit, MI, USA Abstract: The treatment options for metastatic non-small-cell lung cancer (NSCLC) have expanded dramatically in the last 10 years with the discovery of newer drugs and targeted therapy. E...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Thakur MK, Wozniak AJ
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://doaj.org/article/1e1088eece5141f0836f45d248062020
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:1e1088eece5141f0836f45d248062020
record_format dspace
spelling oai:doaj.org-article:1e1088eece5141f0836f45d2480620202021-12-02T07:17:15ZSpotlight on necitumumab in the treatment of non-small-cell lung carcinoma1179-2728https://doaj.org/article/1e1088eece5141f0836f45d2480620202017-02-01T00:00:00Zhttps://www.dovepress.com/spotlight-on-necitumumab-in-the-treatment-of-non-small-cell-lung-carci-peer-reviewed-article-LCTThttps://doaj.org/toc/1179-2728Manish K Thakur, Antoinette J Wozniak, Department of Oncology, Karmanos Cancer Center, Detroit, MI, USA Abstract: The treatment options for metastatic non-small-cell lung cancer (NSCLC) have expanded dramatically in the last 10 years with the discovery of newer drugs and targeted therapy. Epidermal growth factor receptor (EGFR), when aberrantly activated, promotes cell growth and contributes in various ways to the malignant process. EGFR has become an important therapeutic target in a variety of malignancies. Small-molecule tyrosine kinase inhibitors (TKIs) of EGFR are being used to treat advanced NSCLC and are particularly effective in the presence of EGFR mutations. Monoclonal antibodies have also been developed that block the EGFR at the cell surface and work in conjunction with chemotherapy. Necitumumab is a second-generation fully human IgG1 monoclonal antibody that has shown promise in metastatic NSCLC. The benefit has mostly been restricted to squamous cell lung cancer in the frontline setting. Considering that the survival advantage for these patients was modest, there is a need to discover biomarkers that will predict which patients will likely have the best outcomes. This review focuses on the development and clinical trial experience with necitumumab in NSCLC. Keywords: lung cancer, squamous cell, necitumumab, EGFRThakur MKWozniak AJDove Medical Pressarticlelung cancernecitumumabsquamous cell lung cancerNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLung Cancer: Targets and Therapy, Vol Volume 8, Pp 13-19 (2017)
institution DOAJ
collection DOAJ
language EN
topic lung cancer
necitumumab
squamous cell lung cancer
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
spellingShingle lung cancer
necitumumab
squamous cell lung cancer
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Thakur MK
Wozniak AJ
Spotlight on necitumumab in the treatment of non-small-cell lung carcinoma
description Manish K Thakur, Antoinette J Wozniak, Department of Oncology, Karmanos Cancer Center, Detroit, MI, USA Abstract: The treatment options for metastatic non-small-cell lung cancer (NSCLC) have expanded dramatically in the last 10 years with the discovery of newer drugs and targeted therapy. Epidermal growth factor receptor (EGFR), when aberrantly activated, promotes cell growth and contributes in various ways to the malignant process. EGFR has become an important therapeutic target in a variety of malignancies. Small-molecule tyrosine kinase inhibitors (TKIs) of EGFR are being used to treat advanced NSCLC and are particularly effective in the presence of EGFR mutations. Monoclonal antibodies have also been developed that block the EGFR at the cell surface and work in conjunction with chemotherapy. Necitumumab is a second-generation fully human IgG1 monoclonal antibody that has shown promise in metastatic NSCLC. The benefit has mostly been restricted to squamous cell lung cancer in the frontline setting. Considering that the survival advantage for these patients was modest, there is a need to discover biomarkers that will predict which patients will likely have the best outcomes. This review focuses on the development and clinical trial experience with necitumumab in NSCLC. Keywords: lung cancer, squamous cell, necitumumab, EGFR
format article
author Thakur MK
Wozniak AJ
author_facet Thakur MK
Wozniak AJ
author_sort Thakur MK
title Spotlight on necitumumab in the treatment of non-small-cell lung carcinoma
title_short Spotlight on necitumumab in the treatment of non-small-cell lung carcinoma
title_full Spotlight on necitumumab in the treatment of non-small-cell lung carcinoma
title_fullStr Spotlight on necitumumab in the treatment of non-small-cell lung carcinoma
title_full_unstemmed Spotlight on necitumumab in the treatment of non-small-cell lung carcinoma
title_sort spotlight on necitumumab in the treatment of non-small-cell lung carcinoma
publisher Dove Medical Press
publishDate 2017
url https://doaj.org/article/1e1088eece5141f0836f45d248062020
work_keys_str_mv AT thakurmk spotlightonnecitumumabinthetreatmentofnonsmallcelllungcarcinoma
AT wozniakaj spotlightonnecitumumabinthetreatmentofnonsmallcelllungcarcinoma
_version_ 1718399505217355776